Other languages InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Delayed Nasdaq Other stock markets 11:40:10 2024-05-01 am EDT			5-day change	1st Jan Change
0.2725 ^USD	+4.77%		-10.07%	-34.50%

Apr. 18	InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	CI
Apr. 04	InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	Apr. 17
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	Apr. 04
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	Feb. 13
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	Feb. 09
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	Nov. 29
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	Nov. 02
Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901	23-10-24
InMed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29
InMed Pharmaceuticals Inc. Announces Safety and Efficacy Results from its Phase 2 Clinical Trial, Called 755-201-EB	23-06-22
InMed Pharmaceuticals Inc.'s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting	23-06-01
InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15
InMed Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of INM-755 in Epidermolysis Bullosa	23-03-28
InMed Pharmaceuticals Inc. Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating Inm-755 Cannabinol Cream for Epidermolysis Bullosa	23-03-28
Top Premarket Gainers	23-03-20
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-17
Top Premarket Decliners	23-01-05
Top Premarket Gainers	23-01-04
InMed Pharmaceuticals Appoints Jonathan Tegge as Interim Finance Chief	22-12-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Other languages

Filters